Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT ID: NCT02719613
Last Updated: 2025-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
67 participants
INTERVENTIONAL
2016-07-15
2025-11-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
NCT02718833
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04150965
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elotuzumab
This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
Elotuzumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Lenalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Bortezomib
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
Pomalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Nivolumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Elotuzumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
Dexamethasone
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Lenalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Bortezomib
Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
Pomalidomide
Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
Nivolumab
Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving elotuzumab and/or other study drugs at the time of signature of informed consent
* Males and Females, ages 18 and older
Exclusion Criteria
* Participants not receiving clinical benefit from previous study therapy
* Participants who are not medically well enough to receive study therapy as determined by the investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0020
Tucson, Arizona, United States
Local Institution - 0017
Bakersfield, California, United States
Local Institution - 0022
Fountain Valley, California, United States
Local Institution - 0016
West Hollywood, California, United States
Local Institution - 0019
Denver, Colorado, United States
Local Institution - 0021
Jacksonville, Florida, United States
Local Institution - 0042
St. Petersburg, Florida, United States
Local Institution - 0009
Atlanta, Georgia, United States
Local Institution - 0003
Indianapolis, Indiana, United States
Local Institution - 0002
Boston, Massachusetts, United States
Local Institution - 0008
St Louis, Missouri, United States
Local Institution - 0004
New York, New York, United States
Local Institution - 0001
Bethlehem, Pennsylvania, United States
Local Institution - 0018
Dallas, Texas, United States
Local Institution - 0034
Heidelberg, Victoria, Australia
Local Institution - 0023
Antwerp, , Belgium
Local Institution - 0011
Toronto, Ontario, Canada
Local Institution - 0010
Halifax, , Canada
Local Institution - 0035
Athens, , Greece
Local Institution - 0036
Budapest, , Hungary
Local Institution - 0015
Ancona, , Italy
Local Institution - 0012
Florence, , Italy
Local Institution - 0013
Genova, , Italy
Local Institution - 0043
Ravenna, , Italy
Local Institution - 0044
Terni, , Italy
Local Institution - 0014
Torino, , Italy
Local Institution - 0046
Aomori, Aomori, Japan
Local Institution - 0047
Shibukawa-shi, Gunma, Japan
Local Institution - 0049
Osaka, Osaka, Japan
Local Institution - 0048
Koto-ku, Tokyo, Japan
Local Institution - 0050
Chiba, , Japan
Local Institution - 0045
Kasama-shi, , Japan
Local Institution - 0027
Chorzów, , Poland
Local Institution - 0026
Warsaw, , Poland
Local Institution - 0039
Warsaw, , Poland
Local Institution - 0028
Bucharest, , Romania
Local Institution - 0029
Iași, , Romania
Local Institution - 0041
Barcelona, , Spain
Local Institution - 0030
Toledo, , Spain
Local Institution - 0031
Cebeci Ankara, , Turkey (Türkiye)
Local Institution - 0032
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-000037-51
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CA204-185
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.